Management

Nils Brünner
CEO

MD, DMSc.
Professor University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Scandion Oncology shares and warrants
1.077.240 shares and 8.130 warrants of serie TO 1 (Partly owned via Timpco NB ApS)

Carit Andersen
Chief Financial Officer

Cand.Merc.
External lecturer, University of Southern Denmark.

Scandion Oncology shares and warrants
50.578 shares and 5.691 warrants of serie TO 1 (Owned via Decisionconsult Holding ApS)

Jan Stenvang,
Chief Scientific Officer

MSc, PhD.
Associate Professor, University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Scandion Oncology shares and warrants
1.391.064 shares and 0 warrants of serie TO 1

Peter Michael Vestlev
Chief Medical Officer

MD, CBA, MPP.
Chief Physician, Oncologist, Region Sjælland.
Previously, consultant for the Danish Medicines Agency.

Scandion Oncology shares and warrants
50.865 shares and 6.000 warrants of serie TO 1

Nicklas Lindland Roest
Chief Regulatory Officer

MSc. Pharm.

Scandion Oncology shares and warrants
20.041 shares and 6.097 warrants of serie TO 1 (Owned via Lindland Roest Holding ApS)

Annie Rasmussen
Chief Clinical Officer

Registered Nurse, Special Diploma.

Scandion Oncology shares and warrants
3.500 shares and 0 warrants of serie TO 1

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union